Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RET Fusion Testing in Patients With NSCLC: The RETING Study.
Conde E, Hernandez S, Rodriguez Carrillo JL, Martinez R, Alonso M, Curto D, Jimenez B, Caminoa A, Benito A, Garrido P, Clave S, Arriola E, Esteban-Rodriguez I, De Castro J, Sansano I, Felip E, Rojo F, Dómine M, Abdulkader I, Garcia-Gonzalez J, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan-Vidal O, Baixeras N, Nadal E, Cebollero M, Calles A, Martin P, Salas C, Provencio M, Aranda I, Massuti B, Lopez-Vilaro L, Majem M, Paz-Ares L, Lopez-Rios F. Conde E, et al. Among authors: reguart n. JTO Clin Res Rep. 2024 Feb 20;5(4):100653. doi: 10.1016/j.jtocrr.2024.100653. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38525319 Free PMC article.
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Paz-Ares L, et al. Among authors: reguart n. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23. J Clin Oncol. 2023. PMID: 36689692 Free PMC article. Clinical Trial.
Assessment of the change of antiemetic prophylaxis from double to triple combination in patients with high dose carboplatin chemotherapy.
Albanell-Fernández M, Pérez Sánchez Á, Monge-Escartín I, Riu-Viladoms G, Rodríguez Mues MC, Corominas Bosch ML, Gaba García L, Rollán NB, Reguart N, Soy Muner D, Carcelero San Martín E. Albanell-Fernández M, et al. Among authors: reguart n. J Oncol Pharm Pract. 2024 Sep;30(6):999-1009. doi: 10.1177/10781552231194077. Epub 2023 Aug 10. J Oncol Pharm Pract. 2024. PMID: 37563932
Molecular predictors of response to chemotherapy in lung cancer.
Rosell R, Taron M, Ariza A, Barnadas A, Mate JL, Reguart N, Margel M, Felip E, Méndez P, García-Campelo R. Rosell R, et al. Among authors: reguart n. Semin Oncol. 2004 Feb;31(1 Suppl 1):20-7. doi: 10.1053/j.seminoncol.2003.12.011. Semin Oncol. 2004. PMID: 14981577 Review.
Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results.
Reguart N, Viñolas N, Casas F, Gimferrer JM, Agustí C, Molina R, Martin-Richard M, Sanchez-Reyes A, Gascón P. Reguart N, et al. Lung Cancer. 2004 Jul;45(1):67-75. doi: 10.1016/j.lungcan.2003.12.012. Lung Cancer. 2004. PMID: 15196736 Clinical Trial.
The promise of pharmacogenomics: gemcitabine and pemetrexed.
Rosell R, Taron M, Sanchez JM, Moran T, Reguart N, Besse B, Isla D, Massuti B, Alberola V, Sanchez JJ. Rosell R, et al. Among authors: reguart n. Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):70-6. Oncology (Williston Park). 2004. PMID: 15655942 Free article. Review.
156 results